Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ELTK | Eltek | $11.40 | -$2.58 | -2278.03% | 2.7K | $76.5M | $7.65$12.19 |
| MVO | Mv Oil Trust | $2.73 | -$1.28 | -31.92% | 5.6K | $31.4M | $2.59$9.46 |
| ENR | Energizer | $18.54 | -$5.31 | -22.26% | 27.6K | $1.6B | $18.33$39.52 |
| ZGM | Zenta Group | $2.03 | -$0.52 | -20.39% | 31.4K | - | $1.90$4.51 |
| ATGL | Alpha Technology Group | $18.00 | -$3.61 | -16.70% | 576 | $329.8M | $9.01$57.32 |
| NICE | Nice | $108.96 | -$11.90 | -9.85% | 15.9K | $7.5B | $108.90$193.52 |
| INV | Innventure | $3.70 | -$0.33 | -8.19% | 538 | $251.8M | $2.36$14.95 |
| SDOT | Sadot Group | $4.48 | -$0.38 | -7.82% | 23.9K | $5.3M | $4.38$57.00 |
| AFJK | Aimei Health Technology | $11.01 | -$0.69 | -5.90% | 185 | $67.4M | $9.60$41.80 |
| OMCC | Old Market Capital | $4.98 | -$0.27 | -5.14% | 1.1K | $33.6M | $4.21$7.00 |
Related Articles
Featured Article
A Once-in-a-Decade Opportunity: 1 Super Growth Stock Down 48% to Buy Right Now and Hold for a Decade
Josh Kohn-Lindquist|Jun 3, 2025
1 Beaten-Down Growth Stock Down 46% You'll Regret Not Buying on the Dip
Parkev Tatevosian, CFA|Jun 10, 2024
This company helps businesses connect with customers, becoming a more critical part of operations worldwide.
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
Cory Renauer|Dec 23, 2023
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
Wall Street Predicts: 2 Growth Stocks to Skyrocket in 2023
Anders Bylund|Jan 18, 2023
Analysts agree that these two tech stocks should beat the market in 2023. Do their arguments make sense?
The CEO of Boston Omaha Owns a 33% Stake in This Microcap Stock
Bram Berkowitz|Jan 13, 2023
Boston Omaha has been very successful in recent years, and looks set to have a bright future.
These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning
Dan Caplinger|Mar 30, 2022
Markets looked to take a breather after a huge surge in recent weeks.
Should Adagio Say Goodbye to Its COVID-19 Hopes?
Keith Speights and Brian Orelli, PhD|Jan 1, 2022
The prospects for Adagio's experimental COVID antibody therapy appear to be bleak.
Will Adagio's COVID Antibody Therapy Be Too Late to the Party?
Keith Speights and Brian Orelli, PhD|Dec 4, 2021
It's quite possible.
These 2 Stocks Could Double From Here, But for Different Reasons
Daniel Foelber, CFP|Sep 2, 2020
Opportunity for these two companies awaits in the form of solid fundamentals or an extraordinary vision.
Here's How Several Richly Valued Tech Stocks Crashed on Monday's Coronavirus Fears
Anders Bylund|Mar 9, 2020
In many cases, these drops amount to wide-open buying windows for great companies.
